The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Metformin Hydrochloride ER, effective 2026-07-01. This update specifically details the risk of lactic acidosis associated with the drug. The revised warning emphasizes that postmarketing cases have resulted in serious outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias, noting that the onset is often subtle.
Background
The boxed warning, also known as a black box warning, is the strongest warning that the FDA requires for prescription drugs when there is reasonable evidence of a serious hazard. This particular warning for Metformin Hydrochloride ER addresses the potential for lactic acidosis, a rare but severe metabolic complication. The revised language provides more specific information about the presentation and consequences of this adverse event, based on postmarketing experience.
What this means
The revision to the Metformin Hydrochloride ER label underscores the critical importance for clinicians to be vigilant for signs of lactic acidosis. The updated warning highlights that the onset of metformin-associated lactic acidosis is often subtle, making early recognition challenging. Healthcare providers should be aware of the potential for severe outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias, as outlined in the revised warning. Patient advocates and researchers should note the FDA's emphasis on postmarketing data informing this significant label change.
Source
This label revision was issued by the U.S. Food and Drug Administration (FDA), effective 2026-07-01. The details of the revised boxed warning for Metformin Hydrochloride ER are available on dailymed.nlm.nih.gov, an official service of the National Library of Medicine.